<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073307</url>
  </required_header>
  <id_info>
    <org_study_id>11213</org_study_id>
    <nct_id>NCT00073307</nct_id>
  </id_info>
  <brief_title>Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer</brief_title>
  <official_title>A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, efficacy (including quality of life), and
      pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with
      unresectable and/or metastatic renal cell cancer, who have received one prior systemic
      regimen for advanced disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Survival (OS), Patient-reported outcome (PRO)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population</measure>
    <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later</time_frame>
    <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population</measure>
    <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later</time_frame>
    <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final Progression-Free Survival (PFS) - Independent Radiological Review</measure>
    <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.</time_frame>
    <description>PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response - Independent Radiological Review</measure>
    <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.</time_frame>
    <description>Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment</measure>
    <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.</time_frame>
    <description>Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from &quot;0=not at all&quot; to &quot;4=very much&quot; and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment</measure>
    <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.</time_frame>
    <description>Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from &quot;0=not at all&quot; to &quot;4=very much&quot; and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">903</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching in appearance were to be orally administered twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Multi Kinase Inhibitor</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unresectable and/or metastatic, measurable renal cell carcinoma
             histologically or cytologically documented

          -  Patients must have had one prior systemic therapy for advanced disease, which was
             completed at least 30 days but no longer than 8 months prior to randomization

          -  Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI
             according to Response Evaluation Criteria in Solid Tumors (RECIST)

          -  Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of
             0 or 1

          -  Patients who have adequate coagulation, liver and kidney functions

        Exclusion Criteria:

          -  Patients with rare subtypes of renal cell carcinoma (RCC) such as pure papillary cell
             tumors, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma,
             medullary carcinoma, or chromophobe oncocytic tumors

          -  Previous malignancy (except for cervical carcinoma in situ, adequately treated basal
             cell carcinoma,or superficial bladder tumors, or other malignancies curatively treated
             &gt; 2 years prior to entry

          -  Cardiac arrhythmias requiring anti-arrhythmics, symptomatic coronary artery disease or
             ischemia or congestive heart failure

          -  Patients with a history of human immunodeficiency virus (HIV) infection or chronic
             hepatitis B or C

          -  Patients with a history or presence of metastatic brain or meningeal tumors

          -  Patients with seizure disorder requiring medication (such as anti-epileptics)

          -  History of organ allograft or bone marrow transplant of stem cell rescue

          -  Patients who are pregnant or breast-feeding Women of childbearing potential must have
             a negative pregnancy test prior to drug administration. Both men and women enrolled in
             this trial must use adequate birth control

          -  Patients who have three or more of the following:

               -  ECOG performance status greater than or equal to 2,

               -  Abnormally high lactate dehydrogenase,

               -  Abnormally high serum hemoglobin,

               -  Abnormally high corrected serum calcium,

               -  Absence of prior nephrectomy

          -  Excluded therapies and medications, previous and concomitant:

               -  Concurrent anti-cancer chemotherapy, immunotherapy or hormonal therapy except
                  biphosphonates

               -  Significant surgery with 4 weeks of start of study

               -  Investigational drug therapy during or within 30 days

               -  Concomitant treatment with rifampin or St. John's Wort

               -  Prior use of Raf-kinase inhibitors (RKI), MEK or Farnesyl transferase inhibitors

               -  Prior use of Bevacizumab, and all other drugs (investigational or licensed) that
                  target VEGF/VEGF receptors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203-3244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466-2604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fé</city>
        <state>Santa Fe</state>
        <zip>S3000FFV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal-Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>0390</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90619900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caen Cedex 5</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon Cedex</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4004</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-210</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-878</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-043</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <zip>610021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <state>Freestate</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cruces/Barakaldo</city>
        <state>Bilbao</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <zip>115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <state>South Glamorgan</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <state>Stratchclyde</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010 Feb 20;28(6):1054-60. doi: 10.1200/JCO.2009.24.9730. Epub 2010 Jan 19.</citation>
    <PMID>20085939</PMID>
  </results_reference>
  <results_reference>
    <citation>Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr;78(1):24-32. doi: 10.1016/j.critrevonc.2010.03.006. Epub 2010 Apr 18. Review.</citation>
    <PMID>20399677</PMID>
  </results_reference>
  <results_reference>
    <citation>Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22.</citation>
    <PMID>19850637</PMID>
  </results_reference>
  <results_reference>
    <citation>Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2010 Sep;27(3):899-906. doi: 10.1007/s12032-009-9303-z. Epub 2009 Sep 12.</citation>
    <PMID>19757215</PMID>
  </results_reference>
  <results_reference>
    <citation>Peña C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010 Oct 1;16(19):4853-63. doi: 10.1158/1078-0432.CCR-09-3343. Epub 2010 Jul 22.</citation>
    <PMID>20651059</PMID>
  </results_reference>
  <results_reference>
    <citation>Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18.</citation>
    <PMID>19451442</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63. doi: 10.1093/jnci/djn319. Epub 2008 Oct 7.</citation>
    <PMID>18840822</PMID>
  </results_reference>
  <results_reference>
    <citation>Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007 Jun;30(3):220-7.</citation>
    <PMID>17551296</PMID>
  </results_reference>
  <results_reference>
    <citation>Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.</citation>
    <PMID>17215530</PMID>
  </results_reference>
  <results_reference>
    <citation>Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006 Dec 15;12(24):7271-8. Review.</citation>
    <PMID>17189398</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclère J, Roche A, Lassau N. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006 Oct;42(15):2472-9. Epub 2006 Sep 11. Erratum in: Eur J Cancer. 2007 May;43(8):1336.</citation>
    <PMID>16965911</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2003</study_first_submitted>
  <study_first_submitted_qc>November 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2003</study_first_posted>
  <results_first_submitted>August 2, 2011</results_first_submitted>
  <results_first_submitted_qc>November 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2011</results_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Cancer (RCC)</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From randomization start on 01 Dec 2003 to 31 May 2005 [last subject randomized]. One subject randomized in Placebo did not receive treatment. This study was conducted at 120 centers from 19 countries.</recruitment_details>
      <pre_assignment_details>Enrollment included outpatients with documented unresectable and/or metastatic RCC (Renal Cell Carcinoma), and subjects who had 1 prior systemic therapy for advanced disease on which the subject progressed, at least 1 unidimensional measurable lesion, intermediate or low Motzer risk score, life expectancy of 12 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
        </group>
        <group group_id="P3">
          <title>Placebo Randomized, Switch to Sorafenib; Sorafenib Period Only</title>
          <description>Subjects received matching placebo tablets administered orally twice a day(as of ~31 May 2005) when after unblinding subjects switched over to receive Sorafenib orally administered as 2 x 200 mg tablets bid (twice daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind (DB, as of ~31May2005)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="451"/>
                <participants group_id="P2" count="452"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="451"/>
                <participants group_id="P2" count="451"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="299"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with Study medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown reason.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol driven decision point</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>entered Open Label (OL); Sorafenib only</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject did not receive treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label-Sorafenib Only [30Jun2008]</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="0">Placebo treatment ended ~ 31May2005. Those who continued, switched to receive Sorafenib.</participants>
                <participants group_id="P3" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered OL With Sorafenib Only Phase</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="156"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per Investigator, not protocol driven</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to commercial drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to commercial drug (code error)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No record of treatment discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not enter OL/ Sorafenib only phase</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="451"/>
            <count group_id="B2" value="452"/>
            <count group_id="B3" value="903"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" lower_limit="19.0" upper_limit="86.0"/>
                    <measurement group_id="B2" value="59.0" lower_limit="29.0" upper_limit="84.0"/>
                    <measurement group_id="B3" value="59.0" lower_limit="19.0" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="340"/>
                    <measurement group_id="B3" value="655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Motzer Category (Low, intermediate or high)</title>
          <description>The Motzer score risk factors predicting survival in participants with metastatic RCC are as following: • Low ECOG performance status (PS&gt;2) • High lactate dehydrogenase (&gt;1.5 times upper limit of normal) • Low serum hemoglobin (&lt;lower limit of normal) • High corrected serum calcium (&gt;10 mg/dL) • Absence of prior nephrectomy factors.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status (PS)</title>
          <description>ECOG = Eastern cooperative oncology group PS levels are 0 (Fully active, able to carry on all pre-disease performance), 1 (ambulatory and able to carry out work of a light or sedentary), 2 (Ambulatory and capable of all selfcare but unable to carry out any work activities), 3 (Capable of only limited selfcare, confined to bed or chair more than 50% of awake time), 4 (Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair) and 5 (death).</description>
          <units>Participants by scale</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PS 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TNM Classification at study entry</title>
          <description>TNM=Tumor, primary (T); Nodes, regional lymph nodes (N); Metastasis, distant (M). T0/N0/M0=no evidence of aspect. N1=metastasis in single regional lymph node, M1=distant metastasis. T1=tumor 7 cm or less in greatest dimension limited to kidney. T2= tumor &gt;7 cm in greatest dimension limited to kidney. T3=tumor extends into major veins, invades adrenal gland, or peripheric tissues but not beyond Gerota's fascia. T4=tumor invades beyond Gerota's fascia. [Stage I: T1, N0, M0][Stage II=T2, N0, M0][Stage IV=T4, N0, M0; T4, N1, M0; any T, N2, M0; any T, any N, M1][Stage III=remaining combinations]</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="433"/>
                    <measurement group_id="B2" value="438"/>
                    <measurement group_id="B3" value="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Subtypes</title>
          <description>Histopathological characterization of renal cell carcinomas that subjects had included clear cell, papillary or granular carcinomas. Clear cell renal cell carcinoma is a renal cortical tumor typically characterized by malignant epithelial cells with clear cytoplasm and a compact-alveolar (nested) or acinar growth pattern interspersed with intricate, arborizing vasculature.
Tumors in which eosinophilic cells predominate were classified as &quot;granular cell&quot; carcinoma.
Papillary renal cell carcinoma is an uncommon subtype that has distinctive gross, histologic, and cytogenetic features.</description>
          <units>Participants with carcinoma type</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Clear Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                    <measurement group_id="B2" value="447"/>
                    <measurement group_id="B3" value="896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Papillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Granular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population</title>
        <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.</description>
        <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later</time_frame>
        <population>Evaluations based on ITT population. Subjects alive at time of analysis were censored at last date of follow-up (FU) (last visit or contact or at data cut-off date). In case of incomplete date, day was missing, day 15 was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
          </group>
        </group_list>
        <measure>
          <title>Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population</title>
          <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.</description>
          <population>Evaluations based on ITT population. Subjects alive at time of analysis were censored at last date of follow-up (FU) (last visit or contact or at data cut-off date). In case of incomplete date, day was missing, day 15 was used.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="542" lower_limit="500" upper_limit="598"/>
                    <measurement group_id="O2" value="461" lower_limit="408" upper_limit="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size based on primary efficacy endpoint of OS. Clinically meaningful improvement defined as 33.3% improvement in median OS (i.e. HR of 0.75, Sorafenib over Placebo). With overall two-sided alpha of 0.04, 90% power and randomization of 1:1, two formal interim analyses and one final analysis were planned using O'Brien-Fleming type error spending function, and a total of approximately 540 events (deaths) were required for the final analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <p_value_desc>According to O'Brien-Fleming type alpha spending function and total actual deaths at final analysis, threshold for statistical significance was alpha=0.037 (two-sided).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Two treatment groups compared using log-rank test (Sorafenib over Placebo) stratified by country and Motzer category</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population</title>
        <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.</description>
        <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (8Sep2006) for the final OS analysis, approximately 33 months later</time_frame>
        <population>Evaluations based on ITT population. Subjects alive at time of analysis were censored at last date of FU (last visit or contact or at data cut-off date). In case of incomplete date, missing day, day 15 was used. Placebo censored at 30June2005, approximate time of crossover of placebo subjects to sorafenib. NA - not estimable due to censored data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
          </group>
        </group_list>
        <measure>
          <title>Final Overall Survival - Secondary Analysis (Placebo Data Censored at 30June2005) in the ITT Population</title>
          <description>Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks for the first 24 weeks during treatment and every 4 weeks thereafter and approximately every 3 months during post-treatment.</description>
          <population>Evaluations based on ITT population. Subjects alive at time of analysis were censored at last date of FU (last visit or contact or at data cut-off date). In case of incomplete date, missing day, day 15 was used. Placebo censored at 30June2005, approximate time of crossover of placebo subjects to sorafenib. NA - not estimable due to censored data.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="542" lower_limit="500" upper_limit="598"/>
                    <measurement group_id="O2" value="436" lower_limit="385">not estimable due to censored data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size based on primary efficacy endpoint of OS. Clinically meaningful improvement defined as 33.3% improvement in median OS (i.e. HR of 0.75, Sorafenib over Placebo). With overall two-sided alpha of 0.04, 90% power and randomization of 1:1, two formal interim analyses and one final analysis were planned using O'Brien-Fleming type error spending function, and a total of approximately 540 events (deaths) were required for the final analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0287</p_value>
            <p_value_desc>According to O'Brien-Fleming type alpha spending function and total actual deaths at final analysis, threshold for statistical significance was alpha=0.037 (two-sided).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Two treatment groups compared using log-rank test (Sorafenib over Placebo) stratified by country and Motzer category</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Progression-Free Survival (PFS) - Independent Radiological Review</title>
        <description>PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions.</description>
        <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.</time_frame>
        <population>Evaluations based on ITT population as of 28Jan2005 data cut; 769 subjects randomized at that time. PFS determined as time from randomization to actual date of disease progression (PD) (radiological or clinical) or death, if death occurred before PD. Subjects without PD or death at time of analysis were censored at last date of tumor assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets matching in appearance were to be orally administered twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Progression-Free Survival (PFS) - Independent Radiological Review</title>
          <description>PFS determined as the time (days) from the date of randomization at start of study to the actual date of disease progression (PD) (radiological or clinical) or death due to any cause, if death occurred before PD. Outcome measure was assessed approximately every 8 weeks using RECIST v1.0 criteria by independent radiologic review. Radiological PD defined as at least 20% increase in sum of longest diameter (LD) of measured lesions taking as reference smallest sum LD recorded since treatment started or appearance of new lesions.</description>
          <population>Evaluations based on ITT population as of 28Jan2005 data cut; 769 subjects randomized at that time. PFS determined as time from randomization to actual date of disease progression (PD) (radiological or clinical) or death, if death occurred before PD. Subjects without PD or death at time of analysis were censored at last date of tumor assessment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="384"/>
                <count group_id="O2" value="385"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="139" upper_limit="174"/>
                    <measurement group_id="O2" value="84" lower_limit="78" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The planned final PFS analysis was to be performed when approximately 363 progressions or deaths (if death occurred before progression) were observed. The analysis had power of 90% to detect a 50% increase in PFS using a two-sided alpha of 0.01</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.000001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>Two treatment groups compared using log-rank test (Sorafenib over Placebo) stratified by country and Motzer category</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response - Independent Radiological Review</title>
        <description>Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated.</description>
        <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (28Jan2005), approximately 14 months later, tumors assessed every 8 weeks.</time_frame>
        <population>Evaluations of best overall response based on the valid for response population, where as per protocol, subjects were to have first post-baseline tumor evaluation performed at the end of Cycle 1 (6 weeks post-randomization). Of the ITT population that met this criteria as of the 28Jan2005 data cut, 672 subjects were valid for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets matching in appearance were to be orally administered twice a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response - Independent Radiological Review</title>
          <description>Best overall response was determined according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 by independent radiologic review. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased) and not evaluated.</description>
          <population>Evaluations of best overall response based on the valid for response population, where as per protocol, subjects were to have first post-baseline tumor evaluation performed at the end of Cycle 1 (6 weeks post-randomization). Of the ITT population that met this criteria as of the 28Jan2005 data cut, 672 subjects were valid for response.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9"/>
                    <measurement group_id="O2" value="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in response rates (CR+PR)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>difference in response rates (CR+PR) = Placebo - Sorafenib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment</title>
        <description>Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from &quot;0=not at all&quot; to &quot;4=very much&quot; and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL.</description>
        <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.</time_frame>
        <population>Evaluations based on ITT population with a PRO assessment. Day 1, Cycle 1 served as baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQOL) by FKSI-10 (Functional Assessment of General Therapy Kidney Symptom Index 10) Assessment</title>
          <description>Primary Analysis for FKSI-10 patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FKSI-10 patient responses for each question range from &quot;0=not at all&quot; to &quot;4=very much&quot; and after reverse coding the range of values for FKSI-10 total score is from 0 to 40; higher score represents better HRQOL.</description>
          <population>Evaluations based on ITT population with a PRO assessment. Day 1, Cycle 1 served as baseline assessment.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.77" spread="0.23"/>
                    <measurement group_id="O2" value="27.78" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.27" spread="0.22"/>
                    <measurement group_id="O2" value="27.28" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.77" spread="0.25"/>
                    <measurement group_id="O2" value="26.78" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.27" spread="0.30"/>
                    <measurement group_id="O2" value="26.28" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycles 1-5 (Overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.19" spread="0.23"/>
                    <measurement group_id="O2" value="27.20" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Approximately 200 subjects per group, assuming a 10% drop out rate, were required to detect a 2 point difference between sorafenib and placebo at approximately 80% power with a two-sided alpha of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>random coefficient model</method>
            <method_desc>Random coefficient model adjusted for baseline Motzer score, baseline FKSI-10 score and relative day of FKSI-10 completion.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment</title>
        <description>Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from &quot;0=not at all&quot; to &quot;4=very much&quot; and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL.</description>
        <time_frame>From start of randomization of the first subject (1Dec2003) until the data cut-off (31May2005), approximately 18 months later, PRO data collected at Day 1 of each cycle and end of treatment.</time_frame>
        <population>Evaluations based on ITT population with a PRO assessment. Day 1, Cycle 1 served as baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQOL) by Physical Well-Being (PWB) Score of the FACT-G (Functional Assessment of Cancer Therapy-General Version) Assessment</title>
          <description>Primary Analysis for FACT-G (using PWB score) patient-reported outcome (PRO) measure defined as longitudinal analysis of mean score over the first 5 treatment cycles. FACT-G (PWB score) patient responses for each question range from &quot;0=not at all&quot; to &quot;4=very much&quot; and after reverse coding the total FACT-G (PWB score) range of values is from 0 to 28; higher score represents better HRQOL.</description>
          <population>Evaluations based on ITT population with a PRO assessment. Day 1, Cycle 1 served as baseline assessment.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.21" spread="0.17"/>
                    <measurement group_id="O2" value="21.16" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.77" spread="0.17"/>
                    <measurement group_id="O2" value="20.72" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.33" spread="0.19"/>
                    <measurement group_id="O2" value="20.28" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.89" spread="0.24"/>
                    <measurement group_id="O2" value="19.84" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycles 1-5 (Overall)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.70" spread="0.17"/>
                    <measurement group_id="O2" value="20.65" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Approximately 200 subjects per group, assuming a 10% drop out rate, were required to detect a 2 point difference between sorafenib and placebo at approximately 80% power with a two-sided alpha of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>random coefficient model</method>
            <method_desc>Random coefficient model adjusted for baseline Motzer score, baseline PWB score and relative day of PWB completion.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In addition, 1 participant who was not randomized to double-blind treatment received sorafenib treatment on a compassionate-use basis in the crossover phase and was included in the safety population only.</time_frame>
      <desc>DIC (disseminated intravascular coagulation), AT (Atrial tachycardia), NOS (not otherwise specified), GI (gastro-intestinal), CTCAE (Common Terminology Criteria for Adverse Events), ANC (absolute neutrophil count), CNS (central nervous system), CN (cranial nerve), GU (genitourinary)</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib (Nexavar, BAY43-9006)-31May2005 DB</title>
          <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Double Blind period-31May2005</description>
        </group>
        <group group_id="E2">
          <title>Placebo-31May2005 DB</title>
          <description>Subjects received matching placebo tablets administered orally twice a day. [until ~31 May 2005]</description>
        </group>
        <group group_id="E3">
          <title>Sorafenib (Nexavar, BAY43-9006)-30Jun2008</title>
          <description>Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Double Blind-30Jun2008. In addition, 1 participant who was not randomized to double-blind treatment received sorafenib treatment on a compassionate-use basis in the open-label/Sorafenib only phase and was included in the safety population only. Participants affected may deviate from double-blind phase due to data update and cleaning.</description>
        </group>
        <group group_id="E4">
          <title>Placebo ~31May2005, Then Switched to Sorafenib Only-30Jun2008</title>
          <description>Sorafenib period only-30Jun2008: Subjects received matching placebo tablets administered orally twice a day(as of ~31 May 2005) when after unblinding subjects switched over to receive Sorafenib orally administered as 2 x 200 mg tablets bid (twice daily). Open Label/Sorafenib only period-30Jun2008</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v. 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="124" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Blood - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>DIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Arrhythmia, Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia,supraventricular Arrhythmia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia, ATrial Tach/Paroxysmal AT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia, Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Restrictive Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Left Ventricular Diastolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia/Infarction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cardiac General - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ocular - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Colon/Cecum/Appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fistula, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Symptomatic), Esophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Symptomatic), Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Gallbladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Ileum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Small Bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Small Bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Perforation, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Stricture, GI, Biliary Tree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Stricture, GI, Small Bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Ulcer, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death Not Associated With CTCAE Term, Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Death Not Associated With CTCAE Term, Disease Progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Death Not Associated With CTCAE Term, Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Death Not Associated With CTCAE Term, Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Chest/Thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Chest Wall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Extremity-Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Tumor Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Neuralgia/Peripheral Nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Flu-Like Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Syndromes - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Not Coded Yet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Liver Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hepatobiliary - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Allergy - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (Documented Clinically), Blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Catheter-Related</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Meninges (Meningitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Skin (Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Urinary Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection (Documented Clinically), Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, Appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, Catheter-Related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, PANCreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, Pelvis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Normal ANC, Urinary Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Opportunistic Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Unknown ANC, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Unknown ANC, Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Unknown ANC, Lung (Pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Unknown ANC, Meninges (Meningitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Unknown ANC, Upper Airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Infection With Unknown ANC, Urinary Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intraop Injury, Liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Intraop Injury, Extremity - Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Intraop Injury, Bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Intraop Injury, Soft Tissue NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Intraop Injury - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Metabolic/Lab - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Extremity-Upper (Function)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gait/Walking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscle Weakness, Extremity-Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy (Possibly Related To Cancer Treatment)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pyramidal Tract Disfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neuropathy: Cranial, CN VII Motor-Face; Sensory-Taste</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cognitive DisturbANCe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Involuntary Movement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mood Alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neuropathy: Motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Urinary Electrolyte Wasting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Obstruction, GU, Ureter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Edema: Larynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Airway Obstruction, Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness Of Breath)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis, Chemoradiation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Decubitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Wound Complication, Non-Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dermatitis, Radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Skin Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Anus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Stomach</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Jejunum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Lower GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Rectum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Upper GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage With Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage - Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Bronchopulmonary NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Bronchus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Larynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Nose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage Pulmonary, Respiratory Tract NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, Uterus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, Urinary NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Thrombosis/Embolism (Vascular Access)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Thrombosis/Thrombus/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE v. 3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="407" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="346" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="425" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="200" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="111" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="195" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="244" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mucositis (Functional/Symptomatic), Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mucositis (Clinical Exam), Oral Cavity</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>GI - Other</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="221" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Chest/Thorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Extremity-Limb</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Tumor Pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Joint</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Muscle</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal - Other</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Mood Alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Neuropathy: Sensory</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dyspnea (Shortness Of Breath)</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Voice Changes</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="143" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Hand-Foot Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="196" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="451"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="451"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="452"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreed point of publication is 12-18 months after database lock at the earliest.
Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).
No publication of single center data should be done prior of publication if multi -center data.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Per final PFS data (N=769) study unblinded; placebo-randomized subjects switched to sorafenib ~31May2005 (N=216) that diluted final OS, sorafenib treatment effect. Final ITT, N=903, reported safety data include additional data and cleaning.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

